The global calcium oxide market share is witnessing substantial growth, with a valuation of USD 4,573.4 Million in 2022, and ...

BioPhi is an open-source antibody design platform. It features methods for automated antibody humanization (Sapiens), humanness evaluation (OASis) and an interface for computer-assisted antibody ...

After Summit Therapeutics (NASDAQ:SMMT) said early this week that its lead asset ivonescimab outperformed Merck's (NYSE:MRK) blockbuster anti-PD-1 therapy Keytruda in a late-stage trial ...

In an email, the company pointed out that the majority of patients in LITESPARK-005 received Welireg as their third or fourth-line treatment (87.4%) after being treated with PD-1/L1 inhibitor and ...

Merck (MRK) shares fell when Summit Therapeutics (SMMT) reported positive results from a Phase 3 trial of a lung cancer drug that could rival Merck's Keytruda. Summit Therapeutics shares soared to ...

Merck & Co.’s long-running effort to land a punch on small cell lung cancer (SCLC) has racked up a small victory. The drugmaker’s Daiichi Sankyo-partnered antibody-drug conjugate (ADC ...

The trial evaluated monotherapy ivonescimab against monotherapy Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in patients with locally advanced or metastatic non-small cell lung cancer ...

But that doesn’t necessarily threaten the market dominance of Keytruda, a top Merck executive said — and some analysts agree. “I see these results as important, but preliminary,” Merck ...

Ivonescimab slashed the risk of disease progression or death by a whopping 49% compared with Merck’s Keytruda in the phase 3 HARMONi-2 study that Akeso is conducting in Chinese patients with ...